Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | KIN-3248 |
Synonyms | |
Therapy Description |
KIN-3248 is a small molecule pan-FGFR inhibitor with activity against secondary resistance mutations, potentially inhibiting tumor growth (J Clin Oncol 40, 2022 (suppl 4; abstr 461)). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
KIN-3248 | KIN3248|KIN 3248 | FGFR Inhibitor (Pan) 26 | KIN-3248 is a small molecule pan-FGFR inhibitor with activity against secondary resistance mutations, potentially inhibiting tumor growth (J Clin Oncol 40, 2022 (suppl 4; abstr 461)). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR2 G542A FGFR2 V564L FGFR2 amp | stomach cancer | sensitive | KIN-3248 | Preclinical - Pdx | Actionable | In a preclinical study, KIN-3248 treatment inhibited tumor growth in a gastric cancer patient derived xenograft (PDX) model harboring FGFR2 V564L and G542A with FGFR2 amplification (PMID: 38267212). | 38267212 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05242822 | Phase I | KIN-3248 | A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations | Active, not recruiting | USA | ESP | 4 |